NCT03922204: A Study of Bispecific Antibody MCLA-145 in Patients With Advanced Solid Tumors

Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 1
Drug Category: Immunotherapy, Therapeutic Antibody

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: 
Additional Notes: Patients must have received standard therapy for advanced disease
Exclusions: Patients who have received more than 4 prior systemic treatment regimens for advanced or recurrent/metastatic disease; Patients with prior therapy containing an anti-PD-L1 agent or T-cell agonist

Comments are closed.

Up ↑